<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109328">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994564</url>
  </required_header>
  <id_info>
    <org_study_id>356715-1 Dyschromatopsia</org_study_id>
    <nct_id>NCT01994564</nct_id>
  </id_info>
  <brief_title>Prevalence of Dyschromatopsia in Glaucoma Patients</brief_title>
  <official_title>Prevalence of Dyschromatopsia in Glaucoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is a progressive disease resulting in loss of retinal nerve cells and their axons
      (retinal nerve fibers). Retinal nerve fibers are ordered in a special manner when they enter
      the optic nerve. Hence, damage to the retinal nerve fibers by glaucoma results in visual
      field defects at certain locations. Furthermore, the retinal nerve fiber layers from
      different receptors for different colors are ordered in a special manner as well. Thus, it
      is possible that glaucomatous damage causes color vision dysfunction (dyschromatopsia).

      At the moment there is disagreement whether dyschromatopsia occurs at early- to mid-stage or
      only in end-stage glaucoma.

      By testing color vision in glaucoma patients the prevalence of dyschromatopsia in glaucoma
      and in different stages of the disease will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Result from Ishihara Test</measure>
    <time_frame>Visit 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Color vision will be tested once by Ishihara plates. Both eyes will be tested separately.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glaucoma stage</measure>
    <time_frame>Visit 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual field will be tested with 30-2 Humphrey visual field full threshold test. Visual field defects will we graded following the Hodapp‐Anderson‐Parrish Scale (Hodapp E, Parrish RK, Anderson DR. Classification of Defects in Clinical Decisions in Glaucoma. St. Louis: Mosby, 1993:52-61).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of open-angle glaucoma of the Glaucoma Department at
        Massachusetts Eye &amp; Ear Infirmary, Boston, MA 02114, US
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of open angle glaucoma

          -  visual acuity &gt;/= 20/50

          -  age &gt;/= 18 (no upper limit)

          -  male or female gender

        Exclusion Criteria:

          -  other type of glaucoma

          -  age &lt;18

          -  other retinal disease (e.g. age related macular degeneration)

          -  other disease affecting the optic nerve or the retinal nerve fibers

          -  known color blindness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas J. Rhee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye &amp; Ear Infirmary, Harvard Medical School, Boston, MA, US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye &amp; Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OAG</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
